SMi's 9th Annual Pharmaceutical Microbiology UK Conference

SMi Group 20 - 21 January 2020, London, UK.
Pharmaceutical Microbiology as an industry is projected to see significant advancements in the next five years. This forecast is largely attributed to rapid microbiology testing, which has accounted for $3.5 billion last year, while projected to reach nearly double at $6 billion by 2025, and an estimated CAGR of 8.3% leading up to 2025.

At the very core of pharmaceutical microbiology is the accurate and reliable detection of microorganisms that would otherwise contaminate the pharmaceutical products manufactured. This demand for more rapid methods for detection and identification will be accompanied by equally important areas such as: contamination control strategies and environmental monitoring, process automation, and discussing updates to meet regulatory requirements.

Join us at SMi's 9th Annual Pharmaceutical Microbiology Conference to explore novel and developing technologies that tackle the most pressing challenges and push innovation in world of pharmaceutical microbiology.

At the 9th Annual Pharmaceutical Microbiology Conference, you will gain insight into

Featured speakers include

  • Luis Meirinhos-Soares, GMP Inspector, Infarmed IP
  • Jim Polarine, Senior Technical Service Manager, STERIS Corporation
  • Tim Eaton, Sterile Manufacturing Specialist, AstraZeneca
  • Pratixa Patel, Senior Director, Microbiology and Stability Sciences, GSK
  • Ian Symonds, Pharmaceutical Consultant, SDA Pharma
  • Michael Song, Senior Manager, MedImmune
  • Maria Jose Zafra-Domene, Microbiology QC Team Leader, MeiraGTx
  • Ingo Spreitzer, Deputy Head Section Microbial Safety, Paul Ehrlich Institute

Key highlights include for 2020

  • Discuss the regulatory expectations and supportive guidance on bio-contamination control and monitoring in aseptic manufacturing of sterile products from PHSS
  • Gain valuable insight from key opinion leaders in a panel discussion on the impact of the Annex 1 revisions on pharmaceutical microbiology
  • Examine the common myths and urban legends in the pharmaceutical industry related to contamination control from STERIS
  • Explore container closure integrity and controls strategies ensuring product sterility from AstraZeneca
  • Revisit the role of the Official Medicines Control Laboratories as the GMP back up from Infarmed IP

View the full agenda: www.pharma-microbiology.com/wpnWL

Early Bird - Rates

  • Book by 31st October and Save £200
  • Book by 29th November and Save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Intermittent fasting: live 'fast,' live longer?

For many people, the New Year is a time to adopt new habits as a renewed commitment to personal health. Newly enthusiastic fitness buffs pack into gyms and grocery stores...

Pharmacies leave customers hanging when it comes t…

Proper disposal of leftover medication, particularly antibiotics and opioids, can help reduce antibiotic resistance, prevent children from being poisoned and stop the mis...

Scientists find a new use for already known anti-c…

The world scientific community is waging a difficult and prolonged war on cancer. New research in the field of immunogenic cell death can extend the area of drugs applica...

Bayer and Exscientia collaborate to leverage the p…

Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners...

Researchers determine how a specific protein regul…

Immune checkpoints are surface proteins that cancer cells use to evade immune response. These surface proteins are critical for cancer cell growth and drugs targeting the...

Bristol-Myers Squibb completes divestment of manuf…

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufa...

Lynparza approved in the US as a 1st-line maintena…

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US f...

FDA approves first generics of Eliquis

The U.S. Food and Drug Administration has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolis...

Farxiga granted FDA Priority Review for patients w…

AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dap...

Aspirin appears to curb colorectal cancer recurren…

The benefits of a daily aspirin may extend beyond heart health to colorectal cancer treatment, say City of Hope researchers who have found aspirin appears to reduce tumor...

Plant-derived SVC112 hits cancer stem cells, leave…

The red, tube-shaped flowers of the firecracker bush (Bouvardia ternifolia), native to Mexico and the American Southwest, attract hummingbirds. The bush also provides the...

Amgen announces global diagnostic collaborations

Amgen (NASDAQ: AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood- and tissue-based c...